XML 37 R27.htm IDEA: XBRL DOCUMENT v3.19.1

Revenue (Tables)

9 Months Ended

Mar. 31, 2019

Revenue From Contract With Customer [Abstract]

Composition of Total Revenue by Product and U.S versus Rest of World

The following tables present detail regarding the composition of the Company’s total revenue by product and U.S. versus rest of world, “RoW”:

		Three months ended March 31,
		2019												2018
(In millions)		U.S.				RoW				Total				U.S.				RoW				Total
Molecular diagnostic revenues:
Hereditary Cancer Testing		$	114.3			$	3.3			$	117.6			$	110.4			$	2.7			$	113.1
GeneSight			29.6				—				29.6				30.4				—				30.4
Prenatal			30.6				—				30.6				—				—				—
Vectra			11.3				—				11.3				15.0				—				15.0
Prolaris			6.9				—				6.9				6.3				0.1				6.4
EndoPredict			0.5				2.3				2.8				0.2				2.1				2.3
Other			1.5				0.2				1.7				2.0				0.1				2.1
Total molecular diagnostic revenue			194.7				5.8				200.5				164.3				5.0				169.3
Pharmaceutical and clinical service revenue			9.7				6.4				16.1				7.0				6.8				13.8
Total revenue		$	204.4			$	12.2			$	216.6			$	171.3			$	11.8			$	183.1

		Nine months ended March 31,
		2019												2018
(In millions)		U.S.				RoW				Total				U.S.				RoW				Total
Molecular diagnostic revenues:
Hereditary Cancer Testing		$	351.4			$	9.3			$	360.7			$	344.5			$	7.7			$	352.2
GeneSight			82.8				—				82.8				91.0				—				91.0
Prenatal			80.0				—				80.0				—				—				—
Vectra			36.1				—				36.1				40.1				—				40.1
Prolaris			19.1				0.1				19.2				14.3				0.1				14.4
EndoPredict			1.2				6.2				7.4				0.3				5.8				6.1
Other			5.8				0.5				6.3				5.5				0.4				5.9
Total molecular diagnostic revenue			576.4				16.1				592.5				495.7				14.0				509.7
Pharmaceutical and clinical service revenue			25.5				17.7				43.2				22.3				17.8				40.1
Total revenue		$	601.9			$	33.8			$	635.7			$	518.0			$	31.8			$	549.8

Reconciliation of Deferred Revenue Balances

A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:

		Nine months ended
		March 31,
		2019				2018
Deferred revenue - beginning balance		$	2.6			$	2.6
Revenue recognized			(5.9	)			(13.8	)
Prepayments			5.6				13.8
Deferred revenue - Ending Balance		$	2.3			$	2.6

X

- Definition

Tabular disclosure of contract balances and changes in contract balances.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130551-203045

+ Details

Name:	us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration